ATE533494T1 - Mehrfach substituierte selektive androgen- rezeptor-modulatoren und anwendungsverfahren dafür - Google Patents

Mehrfach substituierte selektive androgen- rezeptor-modulatoren und anwendungsverfahren dafür

Info

Publication number
ATE533494T1
ATE533494T1 AT03743665T AT03743665T ATE533494T1 AT E533494 T1 ATE533494 T1 AT E533494T1 AT 03743665 T AT03743665 T AT 03743665T AT 03743665 T AT03743665 T AT 03743665T AT E533494 T1 ATE533494 T1 AT E533494T1
Authority
AT
Austria
Prior art keywords
androgen receptor
androgen
osteoporosis
treatment
conditions
Prior art date
Application number
AT03743665T
Other languages
German (de)
English (en)
Inventor
James Dalton
Duane Miller
Mitchell STEINER
Karen Veverka
Dong Jin Hwang
Jiyun Chen
Original Assignee
Univ Tennessee Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Foundation filed Critical Univ Tennessee Res Foundation
Priority claimed from PCT/US2003/003123 external-priority patent/WO2003074449A2/en
Application granted granted Critical
Publication of ATE533494T1 publication Critical patent/ATE533494T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
AT03743665T 2002-02-28 2003-02-24 Mehrfach substituierte selektive androgen- rezeptor-modulatoren und anwendungsverfahren dafür ATE533494T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45373602P 2002-02-28 2002-02-28
US42338102P 2002-11-04 2002-11-04
PCT/US2003/003123 WO2003074449A2 (en) 2002-02-28 2003-02-24 Multi-substitued selective androgen receptor modulators and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE533494T1 true ATE533494T1 (de) 2011-12-15

Family

ID=33422848

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03743665T ATE533494T1 (de) 2002-02-28 2003-02-24 Mehrfach substituierte selektive androgen- rezeptor-modulatoren und anwendungsverfahren dafür

Country Status (7)

Country Link
US (1) US7705182B2 (enExample)
EP (1) EP1487458B1 (enExample)
JP (2) JP5113979B2 (enExample)
KR (2) KR20040101251A (enExample)
CN (1) CN1700923B (enExample)
AT (1) ATE533494T1 (enExample)
ES (1) ES2528764T3 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
AU2007287070C1 (en) * 2006-08-24 2013-02-14 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
US20090074828A1 (en) 2007-04-04 2009-03-19 Massachusetts Institute Of Technology Poly(amino acid) targeting moieties
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
CA2886498C (en) * 2007-09-11 2017-09-26 Gtx, Inc. Solid forms of selective androgen receptor modulators
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
ATE530169T1 (de) 2007-09-28 2011-11-15 Bind Biosciences Inc Krebszellen-targeting mit nanopartikeln
MX2010003642A (es) 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8791158B2 (en) * 2010-01-11 2014-07-29 Gtx, Inc. Methods of treating meibomian gland dysfunction
JPWO2012020806A1 (ja) 2010-08-11 2013-10-28 旭硝子株式会社 撥水撥油剤組成物および物品
US8395552B2 (en) 2010-11-23 2013-03-12 Metamagnetics, Inc. Antenna module having reduced size, high gain, and increased power efficiency
EP3733170A1 (en) 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US12685719B2 (en) 2012-07-13 2026-07-21 University Of Tennessee Research Foundation Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4/6 inhibitors
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
KR20190077607A (ko) * 2014-10-16 2019-07-03 지티엑스, 인코포레이티드 Sarm을 이용하는 비뇨기 장애의 치료 방법
CN106748884B (zh) * 2016-12-13 2021-08-20 山西振东制药股份有限公司 一种比卡鲁胺中间体的制备方法
WO2019001171A1 (zh) * 2017-06-27 2019-01-03 维眸生物科技上海有限公司 一种含磷化合物及其制备和应用
CN109134533B (zh) 2017-06-27 2020-08-11 维眸生物科技（上海）有限公司 一种含磷化合物及其制备和应用
EP3814272A4 (en) 2018-05-11 2022-03-02 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
CN116348142A (zh) 2020-10-08 2023-06-27 塔尔格免疫治疗有限公司 用于治疗癌症的免疫疗法
WO2023079142A2 (en) 2021-11-05 2023-05-11 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
IL320618A (en) 2022-11-07 2025-07-01 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted pairs containing polyethyleneimine and polyethylene glycol
AU2023376540A1 (en) 2022-11-07 2025-05-15 Targimmune Therapeutics Ag Psma-targeting linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
JP2025540912A (ja) 2022-11-07 2025-12-17 ターグイミューン セラピューティクス アクチエンゲゼルシャフト ポリエチレンイミン及びポリエチレングリコールを含む標的化された線状コンジュゲート並びにそれを含むポリプレックス
CN120641107A (zh) * 2022-11-17 2025-09-12 维眸生物科技(浙江)有限公司 用于治疗炎症性肠病的含磷化合物
WO2025238236A1 (en) 2024-05-16 2025-11-20 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB136001A (en) 1919-01-11 1919-12-11 Frank Harrison An Adjustable Angle, and Surface-marking Plate.
GB1360001A (en) 1971-06-16 1974-07-17 Scherico Ltd Pharmaceutical compositions comprising substituted anilides
US3875229A (en) 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
JPS6044294B2 (ja) 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
DE2862100D1 (en) 1977-10-12 1983-01-05 Ici Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
US4633025A (en) 1985-04-15 1986-12-30 Miles Laboratories, Inc. Method for preparing (+)R-2-methyl-hexane-1,2-diol
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
GB8617652D0 (en) 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
US4977288A (en) 1988-01-29 1990-12-11 President And Fellows Of Harvard College M-aminophenyltrialkylstannane
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
CA2181358A1 (en) 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US5609849A (en) 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
AU717251B2 (en) 1994-12-22 2000-03-23 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
BR9710988A (pt) 1996-06-27 2002-01-15 Ligand Pharm Inc Método e compostos moduladores receptores de androgênio
WO1998005962A1 (en) 1996-08-02 1998-02-12 Panvera Corporation A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US6569896B2 (en) 2000-08-24 2003-05-27 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
AU7604798A (en) 1997-05-30 1998-12-30 University Of Tennessee Research Corporation, The Non-steroidal agonist compounds and their use in male hormone therapy
WO1998055153A1 (en) 1997-06-04 1998-12-10 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
RU2234920C2 (ru) 1999-06-11 2004-08-27 Уотсон Фармасьютикалс, Инк. Введение непероральным путем андрогенных стероидов женщинам
JP2003511467A (ja) 1999-10-14 2003-03-25 ブリストル−マイヤーズ スクイブ カンパニー アンドロゲンレセプターリガンド結合ドメインの結晶構造
PL354620A1 (en) 1999-10-19 2004-02-09 Nobex Corporation Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof
NZ518552A (en) 1999-10-27 2003-10-31 Nobex Corp Resolution of intermediates in the synthesis of substantially pure bicalutamide
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
RU2003102390A (ru) 2000-06-28 2004-05-27 Бристол-Маерс Сквибб Компани (Us) Селективные модуляторы рецептора андрогена и способы их идентификации, изготовления и применения
HUP0303172A3 (en) 2000-06-28 2006-05-29 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, desing and use
IL154425A0 (en) 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
US6998500B2 (en) * 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
PT1463497E (pt) * 2001-12-06 2011-12-20 Gtx Inc Tratamento do desgaste muscular com moduladores selectivos do receptor de androgénios

Also Published As

Publication number Publication date
EP1487458B1 (en) 2011-11-16
US7705182B2 (en) 2010-04-27
KR101088352B1 (ko) 2011-11-30
KR20040101251A (ko) 2004-12-02
JP2005526741A (ja) 2005-09-08
CN1700923B (zh) 2011-06-15
US20060183931A1 (en) 2006-08-17
JP5113979B2 (ja) 2013-01-09
EP1487458A2 (en) 2004-12-22
CN1700923A (zh) 2005-11-23
KR20100103662A (ko) 2010-09-27
ES2528764T3 (es) 2015-02-12
JP2010180245A (ja) 2010-08-19
EP1487458A4 (en) 2006-07-26

Similar Documents

Publication Publication Date Title
EP1487458A4 (en) MULTI-SUBSTITUTED ANDROGEN SELECTIVE RECEPTOR MODULATORS AND METHODS AND USES THEREOF
TW200407280A (en) N-bridged selective androgen receptor modulators and methods of use thereof
TW200503711A (en) Methylene-bridged selective androgen receptor modulators and methods of use thereof
TW200420571A (en) Halogenated selective androgen receptor modulators and methods of use thereof
TW200502249A (en) Heterocyclic selective androgen receptor modulators and methods of use thereof
WO2003074449A3 (en) Multi-substitued selective androgen receptor modulators and methods of use thereof
TW200613252A (en) Metabolites of selective androgen receptor modulators and methods of use thereof
WO2003074473A3 (en) Irreversible selective androgen receptor modulators and methods of use thereof
TW200512180A (en) Large-scale synthesis of selective androgen receptor modulators
TW200503729A (en) Treating androgen deficiency in female (ADIF)-associated conditions with SARMS
BR0307981A (pt) Compostos substituìdos de haloacetamida e azida e seus métodos de uso
MXPA03001632A (es) Moduladores receptores de androgeno selectivos y metodos para usar los mismos.
MX2009000715A (es) Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos.
EA011306B8 (ru) Избирательные модуляторы андрогеновых рецепторов и способы их применения
BG108495A (en) 5-ht receptor ligands and uses thereof
ATE467401T1 (de) Gerät zum mischen und abgeben von knochenzement
TW200502250A (en) Treating androgen decline in aging male (ADAM)-associated conditions with SARMS
MXPA06000119A (es) Profarmacos de moduladores receptores de androgenos selectivos y metodos de uso de los mismos.
WO2007081696A3 (en) Treating androgen decline in aging male (adam)-associated conditions with sarms
EA200401123A1 (ru) Галогенацетамидные и азидзамещённые соединения и способы их применения
BR0308076A (pt) Modulares seletivos receptores de androgênio irreversìveis e seus métodos de uso
DE602006018176D1 (en) N-(4-oxo-3,4-dihydrochinazolin-2-yl)butanamide als androgenrezeptormodulatoren
MXPA05005337A (es) Uso de moduladores de receptor de progesterona selectivos para el tratamiento de deficiencia de androgenos.
UA87852C2 (ru) Выборочные модуляторы андрогеновых рецепторов и их применение
CY1114852T1 (el) Χιμαιρικα μορια αντισωματος rankl-pth/pthrp